SYSTEMATIC REVIEW. Introduction. X. Xue, 1 Z. Ren, 1 A. Zhang, 2 Q. Yang, 3 W. Zhang, 4 F. Liu 1,4
|
|
- Denis Cain
- 5 years ago
- Views:
Transcription
1 SYSTEMATIC REVIEW Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials X. Xue, 1 Z. Ren, 1 A. Zhang, 2 Q. Yang, 3 W. Zhang, 4 F. Liu 1,4 SUMMARY Background: Once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown promising results in the treatment of type 2 diabetes. Herein, we compared the efficacy and safety of once-weekly GLP-1RAs with exenatide and liraglutide separately. Methods: We systematically surveyed the pertinent literature using various databases. The randomised controlled trials that compared once-weekly GLP-1RAs with exenatide and liraglutide in type 2 diabetes were included. Our main end-points were control of glycaemia, body weight, hypoglycaemia and gastrointestinal adverse events (AEs). Results: Our analysis included eight trials involving 5531 patients. Exenatide-long-acting release (LAR), dulaglutide and taspoglutide were more effective than twice-daily exenatide in reducing glycosylated haemoglobin A1c (HbA1c) and fasting blood glucose (FBG) levels and achieving HbA1c targets (< 7.0% and 6.5%). Liraglutide was as effective as dulaglutide and more effective than exenatide-lar and albiglutide in controlling glycaemia. With regard to the effectiveness in decreasing body weight, exenatide-lar, dulaglutide and taspoglutide were similar to exenatide whereas exenatide-lar, dulaglutide and albiglutide were inferior to liraglutide. Once-weekly GLP-1RAs, exenatide and liraglutide resulted in a similar incidence of hypoglycaemia and of gastrointestinal, serious, or other AEs. Conclusions: Once-weekly GLP-1RAs were more effective in controlling glycaemia and equally effective in decreasing body weight than twice-daily exenatide but were inferior to liraglutide in controlling these two parameters (dulaglutide was similar with liraglutide in controlling glycaemia). Once-weekly GLP-1RAs, exenatide and liraglutide had a similar risk of causing AEs. Review criteria Once-weekly GLP-1RAs have shown very promising results in preclinical and clinical trials. This metaanalysis included data from all randomised controlled trials that compared once-weekly GLP-1RAs with exenatide and liraglutide in type 2 diabetes. Message for the clinic There are significant differences between onceweekly GLP-1RAs, exenatide and liraglutide in controlling glycaemia and decreasing body weight. Until now, Liraglutide might be best GLP-1RA in controlling these two parameters. 1 Department of Endocrinology, Tengzhou Central People s Hospital, Shandong, China 2 Zaozhuang Science and Technology College, Shandong, China 3 Department of Medicine, Maternal and Child Care Service Centre of Tengzhou City, Shandong, China 4 Division of Endocrinology and Diabetology, Department of Internal Medicine II, University Hospital of Freiburg, Freiburg, Germany Correspondence to: Fupeng Liu, Division of Endocrinology and Diabetology, Department of Internal Medicine II, University Hospital of Freiburg, Hugstetter Strasse 55, Freiburg, Germany Tel.: Fax: Liufupengsdu@126.com Xianzhong Xue and Zhongfa Ren contributed equally to this research. Introduction Type 2 diabetes is a common and complex metabolic disorder characterised by progressive hyperglycaemia and a high risk of microvascular and macrovascular complications (1 4). Achieving the control of glycaemia and reducing the levels of glycosylated haemoglobin A1c (HbA1c) reduces the risk of long-term microvascular and possibly macrovascular involvement. Optimal treatment of diabetes should address both the control of glycaemia and comorbidities such as obesity, hypertension, and dyslipidemia (5,6). First-line treatments for type 2 diabetes generally include the administration of oral antihyperglycaemic medications and, unless contraindicated, metformin (7,8). However, despite treatment, control of glycaemia becomes more and more ineffective with time and consequently more advanced therapy is required to maintain glycaemic targets (9,10). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of injectable antidiabetic drugs with multiple glucoregulatory effects, including enhancement of glucose-dependent insulin secretion, suppression of inappropriately elevated postprandial glucagon secretion, and slowing of gastric emptying (11 13). In addition to improving the control of glycaemia, they also counteract other diabetes-associated conditions, including obesity, hypertension, and hyperlipidaemia (14,15). GLP-1RAs are widely used as second-line treatments after failure of one or more oral antidiabetic drugs (16,17). Examples of older GLP- 1RAs commonly used in clinical practice include twicedaily exenatide and once-daily liraglutide. Many once-weekly GLP-1RAs have been developed by amino acid substitutions, structural modifications, Disclosure The authors have no financial conflict of interest to declare.. doi: /ijcp
2 650 Once-weekly GLP-1RAs vs. exenatide and liraglutide and novel preparation methods. Several of them have shown very promising results in preclinical and clinical trials. A recent systematic review evaluated the efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes (18). However, they have not focused on the comparison of once-weekly GLP-1RAs vs. exenatide and liraglutide, and it is not very suitable to pool different once-weekly GLP-1RAs together directly. So, we further performed this systemic review comparing the clinical efficacy and safety of once-weekly GLP-1RAs to exenatide and liraglutide. Methods Search strategy and selection criteria This study was designed according to the guidelines of the 2009 Preferred Reporting Items for Systematic Reviews and Meta-analysis statement (19). We selected relevant studies published before 1 October 2015, by searching the MEDLINE ( nlm.nih.gov/pubmed), EMBASE ( and Cochrane Library ( databases using the following search terms in the titles and abstracts (and also in combination with MESH terms): glucagon-like peptide-1 receptor agonist OR exenatide OR liraglutide OR albiglutide OR taspoglutide OR dulaglutide OR lixisenatide OR semaglutide. The study type was limited to randomised controlled trial (RCT) in MEDLINE and EMBASE. No language restriction was used. Unpublished clinical trials were not included in this systematic review. Study selection and data extraction An RCT was considered eligible if the following criteria were met: (i) adult patients with type 2 diabetes were studied; (ii) once-weekly GLP-1RAs, exenatide, and liraglutide were compared; (iii) the intervention duration was at least 12 weeks and (iv) the presence of more than 60 samples in each arm. The exclusion criteria were as follows: (i) observational and retrospective studies; (ii) non-clinical studies and (iii) lack of information about the outcomes that we analysed. Three reviewers selected the potentially publications and assessed the quality of the studies included using the Cochrane risk tool as previous study (15). We extracted the following data from each selected study: study design, baseline measurements, type of intervention, trial sponsors and reporting of the outcomes that we analysed. Statistical analysis We compared the effects of once-weekly GLP-1RAs with exenatide and liraglutide, with no restriction on treatment history. The main outcome was the change in HbA1c level after intervention relative to baseline. The other outcomes assessed were: (i) proportion of participants who achieved an HbA1c target of < 7.0% or 6.5% at the end of intervention; (ii) change in fasting blood glucose (FBG) level between baseline and end of intervention; (iii) change in body weight between baseline and end of intervention; (iv) number of participants with hypoglycaemic episodes; (v) incidence of total, serious and gastrointestinal adverse events (AEs). The pooled outcomes were calculated as either weighted mean difference (WMD, change from baseline) or risk ratio (RR) with 95% confidence intervals (CIs). Standard deviation was calculated from the sample size and the standard error if not reported in the study. I² testing was performed to assess the magnitude of the heterogeneity between the studies, and values greater than 50% indicated moderate-to-high heterogeneity (20). Inverse variance statistical method and random effects analysis model were used to calculate the pooled effect size. To evaluate the influence of each study on the overall effect size, sensitivity analyses were conducted using the leave-one-out method, i.e. by removing one study at a time and repeating the analysis. As a rule of thumb, tests for funnel plot asymmetry should be used only when there are at least 10 studies included in the meta-analysis, because when there are fewer studies the power of the tests is too low to distinguish chance from real asymmetry. So, we have not tested the publication bias in our meta-analysis. All analyses were performed using RevMan software version 5.1 (Nordic Cochrane Centre, Copenhagen, Denmark). Results Search results and study characteristics We identified 1280 studies in the MEDLINE, EMBASE and Cochrane Library databases. Eight RCTs involving 5531 patients were included in our analysis. The study selection process is shown in Figure 1. Five of the eight trials compared once-weekly GLP-1RAs [exenatide-lar (21 23), taspoglutide (24), and dulaglutide (25)] with exenatide 10 lg b.i.d. and three trials compared [exenatide-lar (26), albiglutide(27), and dulaglutide (28)] with liraglutide 1.8 mg q.d. Treatment backgrounds were oral antidiabetic agents (six RCTs) (23 28), and no drugs or oral antidiabetic agents (2 RCTs) (21,22). The mean baseline level of HbA1c was 8.3% (range of ), the mean baseline body mass index was 32.2 kg/m² ( ), and the mean duration of diabetes was 7.6 years ( ). Other characteristics of the 8 RCTs are shown in Table 1.
3 Once-weekly GLP-1RAs vs. exenatide and liraglutide 651 Figure 1 Study selection process Assessment of the risk of bias Seven trials of the eight RTCs were randomised and open-label, indicating that patients and investigators were unmasked to treatment (21 24,26 28). Six trials provided a detailed description of random sequence generation (23 28), six described their methods of allocation concealment (21,24 28), and 5 included blinding of outcome assessments (21,22,24,25,28). The rate of withdrawal for all RCTs was 14.2% (range of %). Analysis of variance (21,22,24), covariance (25,27) or mixed models analysis (23,26,28) was used to assess changes in the HbA1c levels. The risk of bias is summarised and shown in Figures S1 and S2, respectively. Efficacy HbA1c and FBG Comparisons with exenatide. Three trails compared exenatide-lra 2 mg q.w. with exenatide 10 lg b.i.d (21 23). The pooled analysis showed that onceweekly exenatide reduced the mean HbA1c levels more than did exenatide injected twice a day (WMD, 0.46; 95% CI, 0.69 to 0.23; p < 0.01) and increased the proportion of patients who achieved HbA1c levels < 7.0% (RR, 1.52; 95% CI, ; p < 0.01) or 6.5% (RR, 1.65; 95% CI, ; p = 0.02) to a greater extent. Once-weekly exenatide also reduced the mean FBG levels more than did twice-daily exenatide (WMD, 0.83; 95% CI, 1.08 to 0.58; p < 0.01; I 2 = 0%). When the trial by Blevins et al. (21) was excluded, the proportion of patients who achieved HbA1c levels 6.5% became non-significant. All the other results were robust and not affected by any single study included in the analysis. (The detailed results change of HbA1c, change of FBG, patients achieving HbA1c < 7.0%, and patients achieving HbA1c 6.5% were shown in Figures 2, 3, S3, and S4, respectively). Wysham et al. compared dulaglutide with exenatide for 52 weeks (25). Compared with exenatide 10 lg b.i.d., the least square mean changes from baseline were superior for dulaglutide 1.5 mg q.w. ( 0.56%%; p < 0.01) and dulaglutide 0.75 mg q.w. ( 0.27%; p < 0.01). Dulaglutide 1.5 mg q.w. and 0.75 mg q.w. increased the proportion of patients who achieved HbA1c levels < 7.0% (71%, 59% vs. 49%; p < 0.01 for both comparisons) or 6.5% (57%, 48% vs. 35%; p < 0.01 for both comparisons) to a greater extent. At 52 weeks, dulaglutide arms produced greater changes in FBG from baseline compared with exenatide (p < 0.01 for both comparisons). Rosenstock et al. compared taspoglutide with exenatide for 52 weeks (24). Taspoglutide 10 mg q.w. and 20 mg q.w. were significantly superior to exenatide 10 lg b.i.d. in the reduction in HbA1c (estimated difference of 0.22%; p < 0.01, and 0.25%; p < 0.01, for taspoglutide 10 and 20 mg, respectively). Taspoglutide reduced FBG to a greater extent than did exenatide (estimated difference of 0.31 [ 0.62 to 0.01; p = 0.05], and 0.34 [ 0.64 to 0.03; p = 0.03], for taspoglutide 10 and 20 mg, respectively). Comparisons with liraglutide. Dungan et al. compared dulaglutide 1.5 mg q.w. with liraglutide 1.8 mg q.d (28). Dulaglutide showed no significant advantage in decreasing the mean HbA1c and FBG (estimated difference of 0.06% [95% CI, 0.19 to 0.07], and 0.03 [95% CI, 0.32 to 0.25], for HbA1c and FBG, respectively). Moreover, no significant differences were observed in the proportion of patients who achieved HbA1c levels < 7.0% (68% vs. 68%; p = 0.93) and 6.5% (55% vs. 51%; p = 0.36). Pratley et al. evaluated the efficacy of albiglutide 50 mg q.w. with liraglutide 1.8 mg q.d (27). Liraglutide was superior in decreasing the mean HbA1c and FBG [estimated difference of 0.21% (95% CI, 0.08 to 0.34), and 0.46 (95% CI, 0.14 to 0.78), for HbA1c and FBG, respectively] and increased the proportion of patients who achieved
4 652 Once-weekly GLP-1RAs vs. exenatide and liraglutide Table 1 Characteristics of randomised controlled trials included in the systemic review Author Year NCT Number Duration of intervention Treatment background Final Interventions Patients number Sponsor Men (%) Age (year) BMI (kg/m²) HbA1c (%) Diabetes duration (year) Drucker DJ (22) weeks Drug naive, or on one or more oral antidiabetic agents Blevins T (21) weeks Drug naive, or with a stable oral antidiabetic agents Ji L (23) weeks Inadequately controlled with oral antihyperglycaemic medications Rosenstock J (24) weeks Overweight inadequately controlled on metformin a thiazolidinedione Wysham C (25) weeks Treated with metformin and pioglitazone. Buse JB (26) weeks Treated with lifestyle modification and oral antihyperglycaemic drugs Dungan KM (28) weeks Receiving a stable dose of metformin at least for 3 months Pratley RE (27) weeks Inadequate glycaemic control on oral antidiabetic agents E-LAR 2 mg q.w. 148 AstraZeneca E 10 lg b.i.d. 147 E-LAR 2 mg q.w. 129 AstraZeneca; Eli Lilly E 10 lg b.i.d. 123 and Company E-LAR 2 mg q.w. 340 AstraZeneca; Eli Lilly E 10 lg b.i.d. 338 and Company T 10 mg q.w. 384 Hoffmann-La Roche T 20 mg q.w. 392 E 10 lg b.i.d. 373 D 0.75 mg q.w. 280 Eli Lilly and Company D 1.5 mg q.w. 279 E 10 lg b.i.d. 276 E-LAR 2 mg q.w. 461 AstraZeneca; Eli Lilly L 1.8 mg q.d. 450 and Company D 1.5 mg q.w. 299 Eli Lilly and Company L 1.8 mg q.d. 300 A 50 mg q.w. 404 GlaxoSmithKline L 1.8 mg q.d. 408 E-LAR, exenatide long acting release; E, exenatide; L, liraglutide; A, albiglutide; D, dulaglutide; T, taspoglutide.
5 Once-weekly GLP-1RAs vs. exenatide and liraglutide 653 Figure 2 Forest plot of weighted mean difference in change in HbA1c from baseline HbA1c levels < 7.0% (52% vs. 42%; p < 0.01) or 6.5% (28% vs. 20%; p < 0.01) to a greater extent. Buse et al. evaluated the efficacy of exenatide-lar 2 mg q.w. and liraglutide 1.8 mg q.d (26). Similar to the comparison between liraglutide and albiglutide, liraglutide was superior in decreasing the mean HbA1c and FBG [estimated difference of 0.21% (95% CI, 0.08 to 0.33), and 0.36 (95% CI, 0.05 to 0.66), for HbA1c and FBG, respectively] and increased the proportion of patients who achieved HbA1c levels < 7.0% (60% vs. 53%; p = 0.02) to a greater extent. Body weight A pooled analysis from three trials indicated that the effectiveness of exenatide-lar in decreasing body weight was similar to that of exenatide 10 lg b.i.d. (WMD, 0.02; 95% CI, 1.16 to 1.19; p < 0.98) (21 23). Similarly, dulaglutide 1.5 mg, taspoglutide 10 mg, and taspoglutide 20 mg q.w. did not decrease body weight compared with exenatide (24,25). By contrast, liraglutide 1.8 mg q.d. significantly decreased body weight compared with exenatide-lar (26), dulaglutide 1.5 mg (28) and albiglutide 10 mg q.w. (27) (detailed results are shown in Figure 4). Safety Severe hypoglycaemia was very rare, and only two patients who received 10 lg of exenatide twice a day were affected (25). The incidence of minor hypoglycaemia was also very low in patients who received exenatide once weekly (6.8%) and exenatide or liraglutide (8.9%). Pooled results of five trials showed that once-weekly GLP-1RAs significantly decreased the incidence of minor hypoglycaemia compared with exenatide 10 lg b.i.d. (RR, 0.67; 95% CI, ; p < 0.01; I 2 = 0%) (21 25). However, this advantage became non-significant when exenatide-lar (21 23), dulaglutide (25) and taspoglutide (24) were compared with exenatide separately. Exenatide-LAR (26), dulaglutide (28) and albiglutide (27) caused no difference in the incidence of minor hypoglycaemia compared with liraglutide 1.8 mg q.d.
6 654 Once-weekly GLP-1RAs vs. exenatide and liraglutide Figure 3 Forest plot of weighted mean difference in change in FBG from baseline Once-weekly GLP-1RAs did not increase the incidence of serious AEs (RR, 0.97; 95% CI, ; p = 0.78; I 2 = 5%) or other (not including serious) AEs (RR, 0.98; 95% CI, ; p = 0.37; I 2 = 47%) (21 28). These results were robust and not affected by the types of once-weekly GLP-1RAs and by the comparison with exenatide or liraglutide. In general, there was no difference in the incidence of gastrointestinal AEs between once-weekly GLP-RAs and exenatide or liraglutide, although several trials indicated that exenatide-lar was superior to liraglutide in causing nausea, diarrhoea, vomiting, and dyspepsia (26), albiglutide was superior to liraglutide in causing nausea (27), and liraglutide was superior to taspoglutide in causing nausea and vomiting (24). The events examined were nausea (RR, 0.80; p = 0.25) (21 28), diarrhoeal (RR, 1.06; p = 0.64) (21 28), vomiting (RR, 0.83; p = 0.44) (21 28), dyspepsia (RR, 0.93; p = 0.73) (22,24 28) and constipation (RR, 1.22, p = 0.29) (22 28). All these results were robust and not affected by any single study. Discussion Our study assessed the clinical efficacy and safety of once-weekly GLP-1RAs compared with exenatide and liraglutide in patients with type 2 diabetes who were drug-naive or inadequately controlled via oral antihyperglycaemic medication. Patient data from eight RCTs were examined. We found that exenatide-lar, dulaglutide and taspoglutide were more effective than twice-daily exenatide in reducing HbA1c and FBG levels and achieving HbA1c targets (< 7.0% and 6.5%). However, liraglutide was as effective as dulaglutide and more effective than exenatide-lar and albiglutide in controlling glycaemia. Previous studies showed that once-daily liraglutide caused a greater reduction in HbA1c and FBG levels than did twice-daily exenatide in indirect or head-to-head clinical trials (29 34). Therefore, the significantly different results obtained in the comparisons between exenatide and liraglutide primarily reflect their different hypoglycaemic effects. Exenatide-LAR, dulaglutide and taspoglutide did not reduce body weight to a greater extent than did exenatide. However, exenatide-lar, albiglutide and dulaglutide were inferior to liraglutide in decreasing body weight. In the safety analysis, once-weekly GLP-1RAs showed a tendency to decrease the incidence of minor hypoglycaemia compared with exenatide, and in the overall analysis, they did not increase the incidence of gastrointestinal, serious or other AEs.
7 Once-weekly GLP-1RAs vs. exenatide and liraglutide 655 Figure 4 Forest plot of weighted mean difference in change in body weight from baseline Furthermore, once-weekly GLP-1RAs can significantly reduce the patients pain, resulting in better compliance. Patients who switched from short-acting to once-weekly GLP-1RAs reported significant improvements in their quality of life (35). Although most of the included studies were published in high-impact journals, this systemic review has some limitations. First, all RCTs included in our analysis were sponsored by the pharmaceutical industry, and most were open-label owing to different injection frequencies. Second, the RCTs included in our analysis ranged in duration from 24 weeks to 52 weeks (mean of 30 weeks); therefore, whether our findings apply to patients who received once-weekly GLP-RAs for longer periods is unknown. Third, the use of different types of once-weekly GLP-RAs in our analysis resulted in significant heterogeneity, especially in comparison with liraglutide. For this reason, we conducted this analysis by directly comparing the efficacy of GLP-1 RAs. In addition, Ji et al. (23) and Pratley et al. (27) reported HbA1c targets of 7.0% and < 6.5%, respectively. For consistency with other trials, we believe that these values are similar to those used in our study (< 7.0% and 6.5%, respectively). This may influence the validity of our conclusions. In conclusion, exenatide-lar, dulaglutide and taspoglutide were more effective in controlling glycaemia and similarly effective in decreasing body weight compared with twice-daily exenatide. By contrast, liraglutide was superior to exenatide-lar, dulaglutide, and albiglutide in decreasing body weight, and superior to exenatide-lar and albiglutide in controlling glycaemia. In addition, once-weekly exenatide and liraglutide had a similar risk of causing AEs. Acknowledgement None. Funding Fupeng Liu would like to acknowledge the support from The China Scholarship Council.
8 656 Once-weekly GLP-1RAs vs. exenatide and liraglutide References 1 United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995; 18: Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001; 44: S Klein S, Sheard NF, Pi-Sunyer X et al. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care 2004; 27: American Diabetes Association. Standards of medical care in diabetes Diabetes Care 2010; 33: S Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009; 52: International Diabetes Federation. Global Guideline for Type 2 Diabetes, 2012; page (Accessed February 25, 2016). 9 UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: UK Prospective Diabetes Study Group. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care 1998; 21: Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: Kolterman OG, Kim DD, Shen L et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005; 62: Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004; 117: Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012; 344: d Liu FP, Dong JJ, Yang Q et al. Glucagon-like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: a systematic review and meta-analysis. J Diabetes 2015; 7: Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 2013; 17: Karagiannis T, Liakos A, Bekiari E. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab 2015; 17 (11): Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: Blevins T, Pullman J, Malloy J et al. DURATION-5: exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes. J Clin Endocrinol Metab 2011; 96: Drucker DJ, Buse JB, Taylor K et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372: Ji L, Onishi Y, Ahn CW et al. Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus. J Diabetes Investig 2013; 4: Rosenstock J, Balas B, Charbonnel B et al. The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial. Diabetes Care 2013; 36: Wysham C, Blevins T, Arakaki R et al. Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1). Diabetes Care 2014; 37: Buse JB, Nauck M, Forst T et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 2013; 381: Pratley RE, Nauck MA, Barnett AH et al. Onceweekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol 2014; 2: Dungan KM, Povedano ST, Forst T et al. Onceweekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 2014; 384: Nelson P, Poon T, Guan X, Schnabel C, Wintle M, Fineman M. The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. Diabetes Technol Ther 2007; 9: DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin- 4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: Kim D, MacConell L, Zhuang D et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007; 30: Buse JB, Henry RR, Han J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: Zinman B, Hoogwerf BJ, Duran Garcıa S et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007; 146: Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: Buse J, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: Supporting Information Additional Supporting Information may be found online in the supporting information tab for this article: Figure S1. Risk of bias summary. Figure S2. Risk of bias graph. Figure S3. Forest plot of risk ratio in patients achieving HbA1c < 7.0%. Figure S4. Forest plot of risk ratio in patients achieving HbA1c 6.5%. Paper received April 2016, accepted June 2016
exenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited
exenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited 09 December 2011 The Scottish Medicines Consortium (SMC) has completed
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationData from an epidemiologic analysis of
CLINICAL TRIAL RESULTS OF GLP-1 RELATED AGENTS: THE EARLY EVIDENCE Lawrence Blonde, MD, FACP, FACE ABSTRACT Although it is well known that lowering A 1c (also known as glycated hemoglobin) is associated
More informationGlucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol
Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationGLP-1 Agonists for Diabetes
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationThe prevalence of type-2 diabetes is increasing at
Non-insulin injectable therapy The prevalence of type-2 diabetes is rapidly increasing with up to a quarter of people over 60 years of age affected it. To reduce the risk of the associated microvascular
More informationThe first stop for professional medicines advice
London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1 receptor analogues The first stop for professional medicines advice 1 London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationdulaglutide 0.75mg and 1.5mg solution for injection in pre-filled pen (Trulicity ) SMC No. (1110/15) Eli Lilly and Company Ltd.
dulaglutide 0.75mg and 1.5mg solution for injection in pre-filled pen (Trulicity ) SMC No. (1110/15) Eli Lilly and Company Ltd. 04 December 2015 The Scottish Medicines Consortium (SMC) has completed its
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationUpdate on GLP-1 Agonists in Type 2 Diabetes is supported by an educational grant from Novo Nordisk Inc. It has been accredited by the American
Update on GLP-1 Agonists in Type 2 Diabetes is supported by an educational grant from Novo Nordisk Inc. It has been accredited by the American Association of Diabetes Educators (AADE) for nurses, dietitians,
More informationGlucagon-Like Peptide-1 (GLP-1) Agonists
Glucagon-Like Peptide-1 (GLP-1) Agonists Policy Number: 5.01.565 Last Review: 07/2018 Origination: 06/2014 Next Review: 07/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationExecutive Summary. Evaluation of the therapeutic benefits and harms of exenatide 1. IQWiG Reports - Commission No. A05-23
IQWiG Reports - Commission No. A05-23 Evaluation of the therapeutic benefits and harms of exenatide 1 Executive Summary 1 Translation of the executive summary of the final report Bewertung des therapeutischen
More informationSitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP
Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP KEY POINTS sitagliptin (Januvia) is a DPP-4 inhibitor that blocks the breakdown of the
More informationNew Drug Evaluation: Dulaglutide
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationAchieving and maintaining good glycemic control is an
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE; Kathleen Wyne, MD, PhD, FACE, FNLA; Anthony Cannon,
More informationDiabetes: Three Core Deficits
Diabetes: Three Core Deficits Fat Cell Dysfunction Impaired Incretin Function Impaired Appetite Suppression Obesity and Insulin Resistance in Muscle and Liver Hyperglycemia Impaired Insulin Secretion Islet
More informationFrancesca Porcellati
XX Congresso Nazionale AMD Razionali e Benefici dell Aggiunta del GLP-1 RA Short-Acting all Insulina Basale Francesca Porcellati Dipartimento di Medicina Interna, Sezione di Medicina Interna, Endocrinologia
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationThe Highlights of the AWARD Clinical Program FRANCESCO GIORGINO
The Highlights of the AWARD Clinical Program FRANCESCO GIORGINO DEPARTMENT OF EMERGENCY AND ORGAN TRANSPLANTATION SECTION OF INTERNAL MEDICINE, ENDOCRINOLOGY, ANDROLOGY AND METABOLIC DISEASES Disclaimer
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationDM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My!
DM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My! Kevin M. Pantalone, DO, ECNU, CCD Associate Staff Director of Clinical Research Department of Endocrinology Endocrinology and
More informationCurrent evidence on the effect of DPP-4 inhibitor drugs on mortality in type 2 diabetic (T2D) patients: A meta-analysis
Current evidence on the effect of DPP-4 inhibitor drugs on mortality in type 2 diabetic (T2D) patients: A meta-analysis Raja Chakraverty Assistant Professor in Pharmacology Bengal College of Pharmaceutical
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationSelecting GLP-1 RA Treatment
Selecting GLP-1 RA Treatment Dr Felicity Kaplan March 2017 Objectives Review the progressive nature of type 2 diabetes Understand the need for timely treatment intensification Examine the place of GLP-1
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationBeyond A1C. Non-glycemic Effects of GLP-1 Receptor Agonists. Olga Astapova MD, PhD Luis Chavez MD URMC Endocrinology Fellows
Beyond A1C Non-glycemic Effects of GLP-1 Receptor Agonists Olga Astapova MD, PhD Luis Chavez MD URMC Endocrinology Fellows Disclosures No conflicts of interest. Learning Objectives 1. Understand the physiological
More informationHorizon Scanning Technology Summary. Liraglutide for type 2 diabetes. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Liraglutide for type 2 diabetes April 2007 This technology summary is based on information available at the time of research and a limited
More informationScottish Medicines Consortium
Scottish Medicines Consortium liraglutide 6mg/mL prefilled pen for injection (3mL) (Victoza ) Novo Nordisk Ltd. No. (585/09) 06 November 2009 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationPROCEEDINGS CLINICAL RESEARCH AND EXPERIENCE WITH INCRETIN-BASED THERAPIES * Vivian A. Fonseca, MD, FRCP ABSTRACT
CLINICAL RESEARCH AND EXPERIENCE WITH INCRETIN-BASED THERAPIES Vivian A. Fonseca, MD, FRCP ABSTRACT Despite proven lifestyle recommendations and the availability of a range of oral antidiabetic agents,
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationCurrent Status of Incretin Based Therapies in Type 2 Diabetes
Current Status of Incretin Based Therapies in Type 2 Diabetes DR.M.Mukhyaprana Prabhu Professor of Internal Medicine Kasturba Medical College, Manipal, Manipal University, India 2 nd International Endocrine
More informationSELECTED ABSTRACTS AND POSTER PRESENTATIONS
SELECTED ABSTRACTS AND POSTER PRESENTATIONS The following summaries are based on abstracts and posters presented at the American Diabetes Association s 65th Annual Scientific Sessions held in San Diego,
More informationBristol-Myers Squibb / AstraZeneca ADVICE dapagliflozin (Forxiga ) Indication under review: SMC restriction: Chairman, Scottish Medicines Consortium
Re-Submission dapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca 07 February 2014 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationDrug Use Criteria: Glucagon-Like Peptide 1 Receptor Agonists
Texas Vendor Drug Program Drug Use Criteria: Glucagon-Like Peptide 1 Receptor Agonists Publication History Developed February 2006. Revised September 2018; September 2016; June 2015; October 2013; December
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More informationSemaglutide the new kid on the block in the field of glucagonlike peptide-1 receptor agonists?
Editorial Page 1 of 5 Semaglutide the new kid on the block in the field of glucagonlike peptide-1 receptor agonists? Cristian Guja 1,2, Rucsandra Dănciulescu Miulescu 1,2 1 National Institute of Diabetes,
More informationEfficacy and Safety of Initial Combination Therapy in Treatment-Naïve Type 2 Diabetes Patients: A Systematic Review and Meta-analysis
Diabetes Ther (2018) 9:1995 2014 https://doi.org/10.1007/s13300-018-0493-2 ORIGINAL RESEARCH Efficacy and Safety of Initial Combination Therapy in Treatment-Naïve Type 2 Diabetes Patients: A Systematic
More information(Incretin) ( glucagon-like peptide-1 GLP-1 ) GLP-1. GLP-1 ( dipeptidyl peptidase IV DPP IV ) GLP-1 DPP IV GLP-1 exenatide liraglutide FDA 2 2 2
007 18 189-194 (Incretin) Incretin ( ) -1 ( glucagon-like peptide-1 ) ( dipeptidyl peptidase IV ) liraglutide FDA ( Type diabetes mellitus ) -1 ( Glucagon-like peptide-1, ) ( Incretin ) ( Dipeptidyl peptidase
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Reference Number: HIM.PA.53 Effective Date: 03.01.18 Last Review Date: 02.18 Line of Business: Health Insurance Marketplace See Important
More informationT2DM is a global epidemic with
: a new option for the management of type 2 diabetes Marc Evans MRCP, MD, Consultant Diabetologist, Llandough Hospital, Cardiff Incretin-based therapies for the treatment of diabetes mellitus (T2DM) present
More informationGLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION.
GLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION. Patricia Garnica MS, ANP-BC, CDE, CDTC Inpatient Diabetes Nurse Practitioner North
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationLiraglutide (Victoza) in combination with basal insulin for type 2 diabetes
Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes May 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationInjectable GLP 1 therapy: weight loss effects seen in obesity with and without diabetes
Injectable GLP 1 therapy: weight loss effects seen in obesity with and without diabetes Dr Masud Haq Consultant Lead in Diabetes & Endocrinology Maidstone & Tunbridge Wells NHS Trust & The London Preventative
More informationsitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd
sitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd 07 August 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationConvenience of Fixed-Ratio Basal Insulin GLP-1 RA Combination Therapy
Convenience of Fixed-Ratio Basal Insulin GLP-1 RA Combination Therapy Xavier Cos Catalonian Health Institute Barcelona, Spain Stewart B. Harris Western University London, ON, Canada Basal Insulin GLP-1
More informationAbstract. Effect of sitagliptin on glycemic control in patients with type 2 diabetes. Introduction. Abbas Mahdi Rahmah
Effect of sitagliptin on glycemic control in patients with type 2 diabetes Abbas Mahdi Rahmah Correspondence: Dr. Abbas Mahdi Rahmah Consultant Endocrinologist, FRCP (Edin) Director of Iraqi National Diabetes
More informationNew Medicine Assessment Semaglutide (Ozempic ) Treatment of Adults with Insufficiently Controlled Type 2 Diabetes
December 2018 New Medicine Assessment Semaglutide (Ozempic ) Treatment of Adults with Insufficiently Controlled Type 2 Diabetes Recommendation: GREEN Semaglutide is an appropriate treatment option for
More informationA1c Reduction and Weight Loss in a Veteran Population Using GLP-1-RAs
Butler University Digital Commons @ Butler University Undergraduate Honors Thesis Collection Undergraduate Scholarship 5-2017 A1c Reduction and Weight Loss in a Veteran Population Using GLP-1-RAs Shelby
More informationSoliqua (insulin glargine and lixisenatide), Xultophy (insulin degludec and liraglutide)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.48 Subject: Insulin GLP-1 Combinations Page: 1 of 5 Last Review Date: September 15, 2017 Insulin GLP-1
More informationR. Ratner, M. Nauck*, C. Kapitza, V. Asnaghi, M. Boldrin and R. Balena
Original Article: Treatment Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled
More informationLiraglutide: First Once-Daily Human GLP-1 Analogue
DRUG PROFILE KERALA MEDICAL JOURNAL Liraglutide: First Once-Daily Human GLP-1 Analogue Sreejith N Kumar Research Cell, IMA Kerala State, K-5, Kochar Road, Sasthamangalam Thiruvananthapuram* ABSTRACT Published
More informationAlbiglutide, a Once-Weekly GLP-1RA, for the Treatment of Type 2 Diabetes
St. Onge et al. Medical Research Archives, vol. 5, issue 11, November 2017 issue Page 1 of 10 REVIEW ARTICLE Albiglutide, a Once-Weekly GLP-1RA, for the Treatment of Type 2 Diabetes Erin St. Onge 1*, Shannon
More informationGLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks
GLP-1 Receptor Agonists and SGLT-2 Inhibitors Debbie Hicks Prescribing and Adverse Event reporting information is available at this meeting from the AstraZeneca representative The views expressed by the
More informationRole of incretins in the treatment of type 2 diabetes
Role of incretins in the treatment of type 2 diabetes Jens Juul Holst Department of Medical Physiology Panum Institute University of Copenhagen Denmark Diabetes & Obesity Spanish Society of Internal Medicine
More informationScottish Medicines Consortium
Scottish Medicines Consortium saxagliptin, 5mg film-coated tablet (Onglyza ) No. (603/10) Bristol-Myers Squibb Pharmaceuticals Ltd 05 February 2010 The Scottish Medicines Consortium (SMC) has completed
More informationSCIENTIFIC STUDY REPORT
PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established
More informationINJECTABLE THERAPY FOR THE TREATMENT OF DIABETES
INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES ARSHNA SANGHRAJKA DIABETES SPECIALIST PRESCRIBING PHARMACIST OBJECTIVES EXPLORE THE TYPES OF INSULIN AND INJECTABLE DIABETES TREATMENTS AND DEVICES AVAILABLE
More informationEfficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review
Clinical Therapeutics/Volume 34, Number 6, 2012 Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review Vanita R. Aroda, MD 1 ; Robert R. Henry, MD 2 ; Jenny Han,
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationEfficacy and Safety of Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus
Supplement issue Efficacy and Safety of Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus Matthew P. Gilbert, DO, MPH, Richard E. Pratley, MD Diabetes and Metabolism Translational Medicine
More informationClinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Reference Number: HIM.PA.53 Effective Date: Last Review Date: 02.
Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Reference Number: HIM.PA.53 Effective Date: 03.01.18 Last Review Date: 02.19 Line of Business: HIM Revision Log See Important Reminder
More informationChoosing Appropriate Glucagon-like Peptide 1 Receptor Agonists: A Patient-Centered Approach
Diabetes Ther (2014) 5:333 340 DOI 10.1007/s13300-014-0058-y COMMENTARY Choosing Appropriate Glucagon-like Peptide 1 Receptor Agonists: A Patient-Centered Approach Sanjay Kalra To view enhanced content
More informationNCT Number: NCT
Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec 100 U/mL in insulin-naïve adults with type 2 diabetes mellitus: Design and baseline characteristics of the BRIGHT study Alice Cheng
More informationA randomised controlled clinical trial in type 2 diabetes comparing semaglutide to placebo and liraglutide
A randomised controlled clinical trial in type 2 diabetes comparing semaglutide to placebo and liraglutide This trial was conducted in Europe,Asia and Africa. Study participants were randomised evenly
More informationIncredible Incretins Abby Frye, PharmD, BCACP
Incredible Incretins Abby Frye, PharmD, BCACP Objectives & Disclosures Review the pathophysiology of T2DM and the impact of the incretin system Describe the defining characteristics of the available glucagonlike
More informationTargeting simultaneously GLP-1, GIP and glucagon receptors : a new paradigm for treating obesity and diabetes
SHORT COMMENT FOR NATURE REVIEWS ENDOCRINOLOGY Targeting simultaneously GLP-1, GIP and glucagon receptors : a new paradigm for treating obesity and diabetes André J. SCHEEN (1), Nicolas PAQUOT (2) (1)
More informationThis program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) Agonists [Adlyxin (lixisenatide), Byetta (exenatide), Bydureon (exenatide extended-release), Tanzeum (albiglutide), Trulicity (dulaglutide),
More informationORIGINAL ARTICLE. basal insulin, GLP-1 RAs, glycaemic control, meta-analysis, systematic review, type 2 diabetes
Received: 11 July 2016 Revised: 28 September 2016 Accepted: 3 October 2016 DOI 10.1111/dom.12805 ORIGINAL ARTICLE Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment
More informationDrug Class Review Newer Diabetes Medications and Combinations
Drug Class Review Newer Diabetes Medications and Combinations Final Update 2 Report July 2016 The purpose reports is to make available information regarding the comparative clinical effectiveness and harms
More informationClinical study on the therapeutic efficacy of the dipeptidyl peptidase 4 inhibitors, in type 2 diabetes
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA FACULTY OF MEDICINE Clinical study on the therapeutic efficacy of the dipeptidyl peptidase 4 inhibitors, in type 2 diabetes PhD Thesis Abstract Key words:
More informationCase Report Off-Label Use of Liraglutide in the Management of a Pediatric Patient with Type 2 Diabetes Mellitus
Case Reports in Pediatrics Volume 2013, Article ID 703925, 4 pages http://dx.doi.org/10.1155/2013/703925 Case Report Off-Label Use of Liraglutide in the Management of a Pediatric Patient with Type 2 Diabetes
More informationBrigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol
Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol *Please note that this guideline may not be appropriate for all patients
More informationClinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Reference Number: LA.PST.14 Effective Date: 03.18 Last Review Date: 3.18 Line of Business: Medicaid Revision Log 1Revision Log 1Revision
More informationMOA: Long acting glucagon-like peptide 1 receptor agonist
Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication
More informationLe incretine: un passo avanti. Francesco Dotta
Le incretine: un passo avanti Francesco Dotta U.O.C. Diabetologia, Policlinico Le Scotte Università di Siena Fondazione Umberto Di Mario ONLUS Toscana Life Science Park Incretins: multiple targets multiple
More informationA Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
Diabetes Ther (2016) 7:27 43 DOI 10.1007/s13300-016-0155-1 REVIEW A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
More informationOptimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes
Optimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes Philip Raskin, MD Professor of Medicine The University of Texas, Southwestern Medical Center NAMCP Spring
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationBy Eulalia Barajas-Graham
Clinical Review of Incretin Based Therapies: Their Role in the Management of Type 2 Diabetes Mellitus. By Eulalia Barajas-Graham A Capstone Paper submitted to the faculty of the University of North Carolina
More informationARTICLE. B. Charbonnel & H. Steinberg & E. Eymard & L. Xu & P. Thakkar & V. Prabhu & M. J. Davies & S. S. Engel
Diabetologia (2013) 56:1503 1511 DOI 10.1007/s00125-013-2905-1 ARTICLE Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy
More informationDURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
Diabetes Care Publish Ahead of Print, published online March 9, 2010 DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks Running Title: Exenatide once weekly,
More informationDulaglutide (LY ) for the treatment of type 2 diabetes
Expert Review of Clinical Pharmacology ISSN: 1751-2433 (Print) 1751-2441 (Online) Journal homepage: http://www.tandfonline.com/loi/ierj20 (LY-2189265) for the treatment of type 2 diabetes André J. Scheen
More informationCombination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential
REVIEW Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential Nasser Mikhail Endocrinology Division, Olive View-UCLA Medical
More informationTREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse
TREATMENTS FOR TYPE 2 DIABETES Susan Henry Diabetes Specialist Nurse How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management
More informationEffects of Exenatide on Diabetes, Obesity, Cardiovascular Risk Factors, and Hepatic Biomarkers in Patients with Type 2 Diabetes
Journal of Diabetes Science and Technology Volume 2, Issue 2, March 2008 Diabetes Technology Society REVIEW ARTICLE Effects of Exenatide on Diabetes, Obesity, Cardiovascular Risk Factors, and Hepatic Biomarkers
More informationTargeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors. Richard E. Pratley and Matthew Gilbert
REVIEW Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors Richard E. Pratley and Matthew Gilbert Diabetes and Metabolism Translational Medicine Unit, University
More informationCOMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date)
Drug, Treatment, Device name ( Vipidia; Takeda) COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date) Licensed indication To improve glycaemic control in
More information3/8/2011. Julie M. Sease, Pharm D, BCPS, CDE Associate Professor of Pharmacy Practice Presbyterian College School of Pharmacy
Summarize revisions to the 2011 American Diabetes Association clinical practice guidelines. Evaluate bromocriptine as a therapeutic option in the management of type 2 diabetes. Compare and contrast the
More informationBasal & GLP-1 Fixed Combination Use
Basal & GLP-1 Fixed Combination Use Michelle M. Mangual, MD Diplomate of the American board of Internal Medicine and Endocrinology, Diabetes and Metabolism San Juan City hospital Learning Objectives o
More informationThe effect of insulin detemir in combination with liraglutide and metformin compared to liraglutide and metformin in subjects with type 2 diabetes
The effect of insulin detemir in combination with liraglutide and metformin compared to liraglutide and metformin in subjects with type 2 diabetes This trial is conducted in Europe and North America. The
More informationthe person is intolerant of either metformin or a sulphonylurea, or treatment with metformin or a sulphonylurea is contraindicated, and
Exenatide (Byetta) and Liraglutide (Victoza) prescribing guidance: Notes for initiation in primary care These incretin mimetics are given by subcutaneous injection once or twice daily. They have similar
More informationIncretin-Based therapy for type 2 diabetes: overcoming unmet needs
2 : 15 Incretin-Based therapy for type 2 diabetes: overcoming unmet needs Diabetes is a progressive disease characterised by impaired betacell function, and reduced insulin sensitivity and secretion. Over
More informationDURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
Emerging Treatments and Technologies O R I G I N A L A R T I C L E DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks JOHN B. BUSE, MD, PHD 1 DANIEL J.
More informationDPP-4/SGLT2 inhibitor combined therapy for type 2 diabetes
THERAPY REVIEW DPP-4/SGLT2 inhibitor combined therapy for type 2 diabetes STEVE CHAPLIN SPL DPP-4 inhibitors and SGLT2 inhibitors lower blood glucose by complementary mechanisms of action, and two fixeddose
More informationDOI: /jemds/2014/2044 ORIGINAL ARTICLE
AN OBSERVATIONAL STUDY COMPARING SITAGLIPTIN TO METFORMIN AS A INITIAL MONOTHERAPY IN TYPE 2 DIABETES MELLITUS PATIENTS Mohd. Riyaz 1, Imran 2, Rinu Manuel 3, Nidhisha K. Joseph 4 HOW TO CITE THIS ARTICLE:
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More information